Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices (12/2/2020)
Click the Take Course button to access the evaluation.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with RCC.
Upon completion of this activity, participants should be able to:
- Describe the rationale for combining immune checkpoint inhibitors with another immune checkpoint inhibitor or VEGFR TKIs for the treatment of RCC
- Identify patients most likely to benefit from immune checkpoint inhibitor–based combination therapy based on risk and biomarker assessment, along with patient medical and treatment history
- Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
- Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
- Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with RCC
- Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE/CPE activity:
Elizabeth R. Plimack, MD, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Flatiron, Genentech, Janssen, Merck, Pfizer, and Seattle Genetics and funds for research support from Astellas, Bristol-Myers Squibb, Genentech, and Merck.
M. Dror Michaelson, MD, PhD, has disclosed that he has received grants for research support from Eisai, Exelixis, and Pfizer and his spouse holds stock options in Jounce Therapeutics.
Robert Motzer, MD, has disclosed that he has received consulting fees from Eisai, Exelixis, Genentech/Roche, Lilly, Merck Sharp and Dohme, and Pfizer Inc. and research support from Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, and Pfizer Inc.
The activity planning staff listed below disclose no relevant financial relationships:
CCO: Petra Cravens, PhD; Jason J. Everly, PharmD, BCOP, CHCP; Kiran Mir-Hudgeons, PhD; Kevin Obholz, PhD; Timothy A. Quill, PhD; Kristen Rosenthal, PhD; June Wasserstrom
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The NCCN clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD; Angela Motter, PhD
The NCCN clinical staff listed below discloses the following relevant financial relationships:
Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Spouse salary
The CCO staff listed below discloses the following relevant financial relationships:
AstraZeneca: Spouse stock
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-20-113-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation